Search Results

Guerbet, a global specialist in contrast agents and solutions for medical imaging, is reporting its revenue for the first half of 2023.

Guerbet is delighted to announce the success of its teams at the PI-CAI Grand Challenge1, an international challenge organised by a consortium2 of radiology opinion leaders in prostate imaging, urologists and artificial intelligence experts, to compare the performance of artificial intelligence algorithms in the detection of prostate cancer.

Guerbet, a global leader in medical imaging with more than 30 years of experience in MRI, announced its schedule of activities at the 2023 Radiological Society of North America Scientific Assembly and Annual Meeting from November 26-30 in Chicago, IL.

Guerbet, a global specialist in contrast agents and solutions for medical imaging, has published its consolidated financial statements for the 2022 fiscal year.

Guerbet, a global specialist in contrast agents and solutions for medical imaging, has reported its annual revenue.

Guerbet, a global specialist in contrast agents and solutions for medical imaging has announced its strategic priorities for 2023 in a complex international environment characterised by persistent inflationary pressures and the revelation of new business opportunities for products listed in developing markets.

Guerbet, a global leader in medical imaging with more than 30 years of experience in MRI, announced today that based on the most recent scientific and clinical evidence, the ACR Committee on Drugs and Contrast Media has classified Elucirem™ (gadopiclenol) as a Group II agent.

Guerbet, a global specialist in contrast agents and solutions for medical imaging, reported its revenue for the first 9 months of 2022.

Villepinte, Wednesday, September 21, 2022: Guerbet, a global specialist in contrast agents and solutions for medical imaging, is announcing its consolidated results for the first half of 2022.